DashboardPortfoliosWatchlistCommunityDiscoverScreener
  • Community
  • /
  • United States
  • /
  • Healthcare
Author Program NEWCreate Narrative
PLSE logo

Pulse Biosciences, Inc. Stock Price

NasdaqCM:PLSE Community·US$3.8b Market Cap
  • 3 Narratives written by author
  • 0 Comments on narratives written by author
  • 3 Fair Values set on narratives written by author
Author Program NEWCreate Narrative

PLSE Share Price Performance

US$53.11
37.37 (237.42%)
​
US$45.25
Fair Value
US$53.11
37.37 (237.42%)
17.4% overvalued intrinsic discount
US$45.25
Fair Value
Price US$53.11
AnalystConsensusTarget US$45.25
AnalystLowTarget US$32.00
AnalystHighTarget US$58.00
Wed, 26 Aug 26
Fair ValueUS$45.25
Share Pricen/a

PLSE Community Narratives

AN
AnalystConsensusTarget
AnalystConsensusTarget's
Fair Value
·
Fair Value US$45.25 17.4% overvalued intrinsic discount

Nanosecond Pulse Field Ablation Advancements Will Transform Thyroid And Cardiac Care Over Time

0users have liked this narrative
0users have commented on this narrative
2users have followed this narrative
AN
AnalystLowTarget
AnalystLowTarget's
Fair Value
·
Fair Value US$32 66.0% overvalued intrinsic discount

Slower Pulsed Field Ablation Adoption Will Limit Revenue Scale And Delay Profitability

0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
AN
AnalystHighTarget
AnalystHighTarget's
Fair Value
·
Fair Value US$58 8.4% undervalued intrinsic discount

Early Thyroid And Cardiac Applications Will Establish A Powerful Medical Device Platform

0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
PLSE logo
Pulse Biosciences
17.4% overvalued intrinsic discount

Nanosecond Pulse Field Ablation Advancements Will Transform Thyroid And Cardiac Care Over Time

View narrative
AN
AnalystConsensusTarget
AnalystConsensusTarget
Updated 26 Aug
Read Narrative
PLSE logo
Pulse Biosciences
8.4% undervalued intrinsic discount
Updated

Early Thyroid And Cardiac Applications Will Establish A Powerful Medical Device Platform

View narrative
AN
AnalystHighTarget
AnalystHighTarget
Updated 9 Sep
Read Narrative
PLSE logo
Pulse Biosciences
66.0% overvalued intrinsic discount

Slower Pulsed Field Ablation Adoption Will Limit Revenue Scale And Delay Profitability

View narrative
AN
AnalystLowTarget
AnalystLowTarget
Published 7 Aug
Read Narrative

Trending Discussion

No trending discussion available.

Recently Updated Narratives

AN
AnalystHighTarget
PLSE logo

PLSE: Pivotal nsPFA Trials And Early Data Will Drive Bullish Outlook

Fair Value: US$58 8.4% undervalued intrinsic discount
0 fair values setusers have set this as their fair value
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
AN
AnalystConsensusTarget
PLSE logo

PLSE: Pivotal Nanosecond Ablation Data And Partnerships Will Shape 3b Market Access

Fair Value: US$45.25 17.4% overvalued intrinsic discount
2 fair values setusers have set this as their fair value
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
AN
AnalystLowTarget
PLSE logo

Slower Pulsed Field Ablation Adoption Will Limit Revenue Scale And Delay Profitability

Fair Value: US$32 66.0% overvalued intrinsic discount
0 fair values setusers have set this as their fair value
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative

Snowflake Analysis

Flawless balance sheet with limited growth.

2 Risks
1 Reward
View Full Analysis

Pulse Biosciences, Inc. Key Details

US$1.2m

Revenue

US$1.2m

Cost of Revenue

US$3.0k

Gross Profit

US$80.1m

Other Expenses

-US$80.1m

Earnings

Last Reported Earnings
Jun 30, 2026
Next Reporting Earnings
n/a
-1.12
0.25%
-6,755.78%
0%
View Full Analysis

About PLSE

Founded
2014
Employees
116
CEO
Paul LaViolette
WebsiteView website
www.pulsebiosciences.com

Pulse Biosciences, Inc. operates as a novel bioelectric medicine company. It offers nPulse System, a novel Nanosecond Pulsed-Field Ablation delivery platform to treat benign lesions of the skin; nPulse Vybrance Percutaneous Electrode system for soft tissue ablation in surgical setting; nPulse Cardiac Surgical Clamp designed for use in surgical treatment of atrial fibrillation (AF); nPulse Cardiac Catheter System designed to provide a circumferential, or circular, ablation in a single treatment cycle; and nPulse Console, a software-enabled console-based platform designed to accommodate the clinical workflow preferred by physicians. The company was formerly known as Electroblate, Inc. and changed its name to Pulse Biosciences, Inc. in December 2015. Pulse Biosciences, Inc. was incorporated in 2014 and is headquartered in Miami, Florida.

Recent PLSE News & Updates

User avatar
Narrative Update • Sep 09

PLSE: Pivotal nsPFA Trials And Early Data Will Drive Bullish Outlook

Analysts have revised their fair value estimate for Pulse Biosciences to $58 from $35, citing growing confidence in the company's differentiated nanosecond pulse field ablation platform, positive early clinical signals, and the potential impact of ongoing pivotal studies and future partnerships. Analyst Commentary on Pulse Biosciences Recent Street research on Pulse Biosciences has taken a more constructive tone, with several bullish analysts highlighting the company’s nanosecond pulsed field ablation platform and early clinical data as key supports for their valuation work.
User avatar
Narrative Update • Aug 26

PLSE: Pivotal Nanosecond Ablation Data And Partnerships Will Shape 3b Market Access

Analysts have lifted the fair value estimate for Pulse Biosciences to $45.25 from $41, citing Street research that highlights its differentiated nanosecond pulsed field ablation platform, positive early clinical data, progress in pivotal studies, and what they view as improving success probabilities following recent updates. Analyst Commentary Recent Street research on Pulse Biosciences centers on the potential of its nanosecond pulsed field ablation platform, the pace of clinical development, and how these factors feed into valuation and execution risk for investors following the story into late 2026.
User avatar
Narrative Update • Aug 12

PLSE: Clinical And Regulatory Progress Will Test Access To 3b Ablation Market

The analyst price target for Pulse Biosciences has been reset from about $30.67 to $41.00, with analysts pointing to improving success probabilities for its nanosecond pulsed field ablation platform and continued clinical and regulatory progress as key drivers of their updated views. Analyst Commentary Recent Street research on Pulse Biosciences highlights both optimism around the nanosecond pulsed field ablation platform and a focus on the execution risks that come with an early stage commercial story.

Recent updates

No updates

Pulse Biosciences, Inc. Competitors

THC logo

Tenet Healthcare

Symbol: NYSE:THC
Market cap: US$21.2b
GH logo

Guardant Health

Symbol: NasdaqGS:GH
Market cap: US$21.1b
STE logo

STERIS

Symbol: NYSE:STE
Market cap: US$20.5b
ZBH logo

Zimmer Biomet Holdings

Symbol: NYSE:ZBH
Market cap: US$17.8b
View more competitors

Make Better Investing Decisions Anywhere

Scan to download
Open AppStoreOpen Google Play
Chrome Web Store
Level 5, 320 Pitt Street, Sydney
Financial Data provided by S&P Global Market Intelligence LLC, analysis provided by Simply Wall Street Pty Ltd. Copyright © 2026, S&P Global Market Intelligence LLC. All rights reserved.
View Data Sources
Markets
  • US: NYSE & NASDAQ
  • UK: FTSE
  • Australia: ASX
  • India: NIFTY
  • Canada: TSX
  • South Africa: JSE
  • Japan: NIKKEI
  • South Korea: KOSPI
  • Germany: DAX
Investing Ideas
  • Undervalued Companies
  • Dividend Powerhouses
  • Insider Buying
  • Nuclear Energy
  • Autonomous Vehicles
  • Artificial Intelligence
  • Crypto and Blockchain
  • Cybersecurity
  • More ideas
Stock Communities
  • AstraZeneca
  • HSBC Holdings
  • Shell
  • Unilever
  • Diageo
  • Rio Tinto Group
  • RELX
  • BP
  • Barclays
Features & Tools
  • Portfolio Tracker
  • Stock Screener & Alerts
  • Narratives & Fair Values
  • Dividend Calculator
News & Discovery
  • Latest Stock News
  • Global Market Insights
  • The Foxhole
  • Investing Ideas
  • Community Narratives
  • What's New
Simply Wall St
  • Plans & Pricing
  • Advertising
  • About Us
  • Contact Us
  • Careers
  • Help Center
  • Learn Stock Investing
  • Affiliate Program
  • Business & Enterprise
  • Charlie AI
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.
© 2026 Simply Wall Street Pty Ltd, US Design Patent #29/544/281, Community and European Design Registration #2845206
  • Terms and Conditions
  • Privacy Policy
  • AI Terms
  • Financial Services Guide